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Abstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and 
currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, 
liraglutide binds non-covalently to albumin, giving it a pharmacokinetic proﬁ  le suitable for once-
daily administration. In clinical trials of up to 1 year duration, liraglutide has been demonstrated 
to have beneﬁ  cial effects on islet cell function, leading to improvements in glycemic control. 
Both fasting and postprandial glucose concentrations are lowered, and are associated with lasting 
reductions in HbA1c levels. Liraglutide is effective as monotherapy and in combination therapy 
with oral antidiabetic drugs, and reduces HbA1c by up to ∼1.5% from baseline (8.2%–8.4%). 
Because of the glucose-dependency of its action, there is a low incidence of hypoglycemia. 
Liraglutide is associated with body weight loss, and reductions in systolic blood pressure have 
been observed throughout the clinical trials. The most common adverse events reported with 
liraglutide are gastrointestinal (nausea, vomiting and diarrhea). These tend to be most pronounced 
during the initial period of therapy and decline with time. Further clinical experience with lira-
glutide will reveal its long-term durability, safety and efﬁ  cacy.
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Introduction
Type 2 diabetes mellitus (T2DM) is a progressive disease, characterized by both insulin 
resistance and declining β-cell function which lead to impaired glucose-induced insulin 
secretion. Once insulin secretion can no longer compensate for the insulin resistance, 
hyperglycemia ensues, and with it, the development of micro- and macrovascular 
diabetic complications and associated increases in morbidity and mortality. Current 
treatment algorithms advocate the early use of metformin, together with lifestyle inter-
ventions (dietary modiﬁ  cation, increased physical activity, weight loss) to control the 
hyperglycemia.1 However, for the majority of patients, this is insufﬁ  cient, and most 
progress to require the use of several agents including insulin. Unfortunately, even 
with this approach, several long-term clinical trials (eg, United Kingdom Prospective 
Diabetes Study (UKPDS); A Diabetes Outcome Progression Trial (ADOPT)) have 
demonstrated that HbA1c levels continue to rise over time,2–4 underscoring the need for 
new and more efﬁ  cacious agents which not only target treatment, but also prevention 
of the disease, its progression and its associated complications.
One new approach is based upon the actions of the intestinal hormone glucagon-like 
peptide-1 (GLP-1). GLP-1, together with glucose-dependent insulinotropic polypeptide 
(GIP), is an incretin hormone which enhances meal-induced insulin secretion, while 
also having a number of other actions considered desirable in an anti-diabetic agent 
(Table 1).5–7 Thus, GLP-1 stimulates all steps in insulin biosynthesis and secretion, and 
has beneﬁ  cial effects on both β-cell function and survival. It reduces excessive hepatic 
glucose production by suppressing glucagon secretion, it delays gastric emptying, lead-
ing to lower postprandial glucose excursions, and it has central effects to reduce appetite Vascular Health and Risk Management 2009:5 200
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and food intake, resulting in body weight loss, while more 
recent studies point to beneﬁ  cial cardiovascular effects.5–7 
GIP has similar effects to GLP-1 on the β-cells, but it does 
not inhibit glucagon secretion, and has only minimal effects 
on gastric emptying. Appetite is unaffected by GIP, but GIP 
has been implicated in the control of lipid metabolism, and 
may have a role in the regulation of bone remodeling.5
When given as an intravenous infusion, GLP-1 has been 
demonstrated to normalize both fasting and postprandial 
plasma glucose concentrations in patients with T2DM,8,9 
whilst continuous subcutaneous administration greatly 
improves metabolic control, lowering glucose proﬁ  les and 
HbA1c levels, improving β-cell function and reducing body 
weight over a 6-week period.10 However, GLP-1 is extensively 
degraded in vivo,11 primarily by the enzyme dipeptidyl pepti-
dase-4 (DPP-4), with such rapidity that its apparent half-life 
is only in the order of 1 to 2 minutes and its metabolic clear-
ance rate exceeds the cardiac output by 2- to 3-fold,12,13 with 
the resultant metabolite lacking insulinotropic effects. Other 
enzymes, such as netutral endopeptidase 24.11 (NEP) are also 
able to cleave GLP-1 in vivo,14 while furthermore, the peptide 
is efﬁ  ciently cleared by the kidneys at a rate which exceeds 
the glomerular ﬁ  ltration rate.15 Together, these factors mean 
that the native peptide cannot be used therapeutically, and 
there has, therefore, been much effort placed upon identifying 
metabolically stable analogs or derivatives of GLP-1 which 
are not subject to the same enzymatic degradation or renal 
clearance. Although a simple substitution of the penultimate 
N-terminal amino acid prevents degradation by DPP-4, these 
analogs are still rapidly cleared by the kidneys.16 In the search 
for more stable analogs, two distinct groups of compounds 
have attracted much interest: (i) compounds based upon 
mammalian GLP-1, which have been modiﬁ  ed to facilitate 
binding to plasma proteins, such as albumin, to protract their 
action and (ii) compounds which are based upon the sequence 
of exendin-4, a naturally occurring peptide originally isolated 
from the saliva of the Gila monster (Heloderma suspectum), 
which shares 53% homology with GLP-1 and is a full agonist 
at the GLP-1 receptor.17 Exendin-4 is resistant to DPP-4, 
and is cleared from the plasma exclusively by glomerular 
ﬁ  ltration.15
This article focuses upon liraglutide, being developed 
by Novo Nordisk, which is based upon mammalian GLP-1. 
Novo Nordisk submitted a new drug application (NDA) to 
the food and drug administration (FDA) in the United States 
and a marketing authorization application to the European 
Medicines Agency (EMEA) in Europe in May 2008. An 
NDA was submitted to the Japanese regulatory authorities 
in July 2008.
Liraglutide
Chemistry and pharmacokinetics
Liraglutide (γ-L-glutamoyl(N-α-hexadecanoyl)-Lys,26 
Arg34-GLP-1(7–37)) is an acylated derivative of mammalian 
GLP-1, sharing 97% sequence homology with the native 
peptide (Figure 1). It is based upon the sequence of GLP-1 
(7–37), with the addition of a glutamic acid residue at posi-
tion 26, allowing attachment of a palmitoyl group, and a 
substitution (arginine instead of lysine) at position 34.18 In 
vitro studies show that, despite the modiﬁ  cations, liraglutide 
retains afﬁ  nity for the GLP-1 receptor.18 The palmitoyl group 
facilitates non-covalent binding to albumin after injection, 
Table 1 Actions of GLP-1
Type 2 diabetic phenotype Actions of GLP-1
Impaired β-cell function Increases insulin secretion (glucose-dependent) and biosynthesis
Improves β-cell function (glucose sensitivity, proinsulin:insulin ratio, HOMA-β)
Upregulates other genes essential for β-cell function (eg, GLUT 2, glucokinase)
Reduced β-cell mass Increases β-cell proliferation/differentiationa
Reduces β-cell apoptosisa
Increases β-cell massa
Glucagon hypersecretion Reduces glucagon secretion (glucose-dependent)
Postprandial hyperglycemia Delays gastric emptying
Overeating, obesity Delays gastric emptying, increases satiety, reduces appetite → decreased food intake and body weight
Macrovascular complications Beneﬁ  cial cardiovascular effects
Insulin resistance Improvements in insulin sensitivityb
Note: For a review, see5–7
aEffects shown only in preclinical in vitro and animal studies.
bAction which is likely to be secondary to improvements in metabolism rather than a direct effect of GLP-1.Vascular Health and Risk Management 2009:5 201
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whereby the peptide escapes glomerular ﬁ  ltration. Together 
with self-association, this results in a pharmacokinetic proﬁ  le 
with slow absorption (Tmax of ∼10–14 hours) and a long 
half-life of around 12½ hours after subcutaneous injection,19 
making it suitable for once-daily administration. Although 
liraglutide is metabolized slowly in vitro by DPP-4 and 
NEP,20 in vivo, the albumin binding is likely to hinder enzy-
matic access to the molecule, while furthermore, acting as a 
buffer reservoir, which contributes to the long half-life of the 
compound. Thus, in vivo, the majority of liraglutide (89%) is 
found in the plasma as the intact molecule. No intact liraglutide 
and only low levels of metabolites were detected in the urine 
or feces, suggesting that liraglutide is probably degraded at a 
very slow rate into small peptides, amino acids and fatty acid 
fragments which are subsequently eliminated via the liver and 
kidney, or recycled into new endogenous proteins and lipids.20 
Perhaps because of this, a pharmacokinetic study indicated 
that dose-adjustment was unnecessary in subjects with renal 
impairment.21 When adjusted for body weight, age or gender 
has no effect upon the pharmacokinetics of liraglutide (1 mg) 
in healthy subjects;22 dose-dependent increases in exposure 
are seen with doses up to 12.5 μg/kg, but the t½ remains 
constant.19 These ﬁ  ndings were subsequently reproduced using 
doses up to 25 μg/kg in healthy Japanese subjects.23
Early clinical studies
Early clinical studies with liraglutide showed that a single 
subcutaneous injection (10 μg/kg) reduced both fasting 
and postprandial blood glucose concentration in subjects 
with T2DM.24 Subsequently, treatment with liraglutide 
(6 μg/kg) for 1 week improved both α- and β-cell function, 
resulting in improved 24-hour glycemic control in patients 
with T2DM .25
Eight weeks of treatment with liraglutide (0.6 mg) in 
obese subjects with T2DM (baseline HbA1c 7.5%) signiﬁ  -
cantly reduced glycemia (−0.33% for liraglutide, +0.47% 
for placebo), but had no signiﬁ  cant effect on body weight 
(−0.7 kg for liraglutide, −0.9 kg for placebo). In this study,26 
body composition was assessed, showing that liraglutide 
was associated with small (non-signiﬁ  cant) trends towards 
a reduction in total fat mass and an increase in lean body 
mass. Overall 24-hour energy expenditure was not affected 
by liraglutide treatment.26
In a 12-week randomized, placebo-controlled dose-
response study (baseline HbA1c 7.6%), monotherapy with 
liraglutide in doses of 0.045 up to 0.75 mg led to reductions in 
HbA1c with all but the lowest dose.27 Compared with placebo, 
the two highest doses of liraglutide (0.60 and 0.75 mg) 
resulted in HbA1c changes of −0.70% and −0.75% after 
12 weeks, which were similar to the reduction obtained with 
the active comparator (glimepiride, −0.74%). Fasting plasma 
glucose (FPG) levels also decreased, with the maximal 
effect being observed after the ﬁ  rst week of treatment and 
maintained over the 12-week study period. As with the effect 
on HbA1c, the effect of the two highest doses of liraglutide 
was comparable to that of glimepiride. In this study, body 
weight did not increase, but there was no clear dose-response 
relationship; a signiﬁ  cant reduction (−1.2 kg) was obtained 
with the 0.45 mg dose but not with the two highest liraglu-
tide doses.27
In another dose-response study, patients with T2DM 
discontinued their usual oral anti-diabetic drug (OAD) and 
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Figure 1 Primary structure of liraglutide (shaded residues indicate differences from mammalian GLP-1).Vascular Health and Risk Management 2009:5 202
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entered a metformin run-in period (500 mg bid for 2 weeks, 
1000 mg bid for 2 weeks) before being randomized to lira-
glutide monotherapy (0.045 up to 0.75 mg) or continuing 
metformin (1000 mg bid) for 12 weeks.28 The two lowest 
doses of liraglutide (0.045 and 0.225 mg) were insufﬁ  cient 
to maintain the glycemic control obtained with metformin 
(baseline HbA1c ∼7%), but the three highest doses (0.45, 0.6 
and 0.75 mg) were comparable to metformin (change in 
HbA1c, +0.22%, +0.16% and +0.30%, respectively vs 
+0.09% for metformin at week 12).28 Relative to baseline, 
all liraglutide doses led to weight loss over the 12 weeks, 
which was, however, not signiﬁ  cantly different compared 
with metformin, and again, no clear dose-response relation-
ship was apparent. All treatment groups except for the lowest 
liraglutide dose (0.045 mg) showed a decrease in total body 
mass and total fat mass which was comparable to that induced 
by metformin alone.28 Mathematical modeling of the results, 
however, suggested that the dose range in this trial was likely 
to have been sub-optimal in terms of HbA1c reduction.
Collectively, therefore, these results indicated that 
higher doses of liraglutide may have greater efﬁ  cacy, and 
subsequently, Nauck et al29 investigated the effect of higher 
doses of liraglutide (titrated weekly in 0.5 mg increments 
from 0.5 to 2.0 mg) in a randomized double-blinded placebo-
controlled protocol in patients with poorly controlled 
diabetes (HbA1c ∼9.4%). Subjects on metformin mono-
therapy (1000 mg bid) were randomized to receive continu-
ing metformin monotherapy, metformin plus the addition of 
liraglutide, or liraglutide monotherapy. In addition, an open-
label group received metformin plus glimepiride. FPG levels 
remained unchanged on metformin monotherapy, whereas 
they were reduced by 1.4 mmol/L in the subjects switched 
from metformin to liraglutide monotherapy. When com-
pared to metformin monotherapy, the addition of liraglutide 
resulted in a further reduction of 3.9 mmol/L after 5 weeks 
of treatment, accompanied by a 0.8% reduction in HbA1c 
(baseline HbA1c ∼9.4%). Furthermore, the combination of 
metformin plus liraglutide gave a greater reduction in FPG 
levels compared with metformin plus glimeperide (between 
group difference of 1.4 mmol/L in favor of liraglutide). In 
terms of body weight, both liraglutide as monotherapy and in 
combination with metformin led to body weight reductions 
(−2.1 and −2.2 kg from baseline, respectively) compared 
with metformin (−1.7 kg) and metformin plus glimepiride 
(+0.8 kg) after 5 weeks of treatment. Treatment effects on 
body weight and fasting glucose remained largely unchanged 
when patients experiencing nausea for more than 1 week 
were excluded from the analysis.29
In a 14-week study (n = 165) investigating the efﬁ  cacy 
of liraglutide monotherapy, HbA1c was dose-dependently 
reduced from baseline (∼8.3%) by 0.98%, 1.40% and 1.45% 
for liraglutide doses of 0.65, 1.25 and 1.90 mg, respectively, 
compared with an increase of +0.29% for placebo, with 46% 
of patients reaching the HbA1c goal of 7% (compared to 5% 
on placebo).30 There were dose-related reductions in FPG (of 
between 2.7 and 3.4 mmol/L), and postprandial glucose was 
also signiﬁ  cantly reduced by liraglutide. Body weight fell in 
all liraglutide groups (by up to 3.0 kg for the 1.9 mg dose).
In Japanese subjects with T2DM (n = 226, baseline HbA1c 
8.3%), liraglutide (0.1–0.9 mg) dose-dependently reduced 
HbA1c levels by 0.79 up to 1.85% relative to placebo treat-
ment by week 14, with 75% and 57% of subjects reaching 
target HbA1c levels of 7% and 6.5%, respectively, with 
the highest dose (vs 9 and 2%, respectively, of subjects on 
placebo).31 Notably, in this study the HbA1c-lowering effect 
appeared to plateau at a dose of 0.9 mg, whereas in Caucasians, 
doses up to 1.9 mg are required for maximal efﬁ  cacy.30 This 
is most likely explained by the different nature of T2DM in 
Japanese diabetes, where β-cell dysfunction appears to play 
a greater role than insulin resistance.32 There were also dose-
dependent reductions in FPG (by up to 2.5 mmol/L relative to 
placebo) and postprandial glucose.31 In this study in lean sub-
jects (weight ∼63 kg, BMI ∼24 kg/m2), body weight remained 
relatively stable (changes ranging from +0.1 to −0.5 kg with 
liraglutide, vs −1.0 kg with placebo).31
Liraglutide effect and action 
in diabetes (LEAD) studies
The LEAD program comprises six randomized, controlled, 
double-blind phase 3 studies in patients with inadequately 
controlled T2DM, designed to investigate the efﬁ  cacy of 
liraglitide as monotherapy or as combination therapy with 
one or two OADs (Table 2). In all the trials, the liraglutide 
dose was initiated at 0.6 mg/day for 1 week and titrated by 
weekly increments of 0.6 mg to the ﬁ  nal dose. Most of the 
LEAD studies included an active comparator.
LEAD-1 is a 26-week placebo-controlled study in 1041 
patients with T2DM on background glimepiride (2–4 mg/day) 
therapy (baseline HbA1c ∼8.4%), designed to compare the 
effects of using liraglutide (0.6, 1.2 or 1.8 mg once daily) or 
rosiglitazone (4 mg/day) as add-on therapy to sulfonylurea; 
preliminary results were presented at the annual meetings of 
the ADA and EASD.33,34 In this study, the addition of lira-
glutide or rosiglitazone gave additional reductions in HbA1c 
compared to placebo, where HbA1c levels increased by 
0.23% from baseline. Addition of rosiglitazone or the lowest Vascular Health and Risk Management 2009:5 203
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liraglutide dose (0.6 mg) lowered HbA1c to a similar extent 
(−0.44% and −0.60%, respectively), whereas the two high-
est liraglutide doses were comparable and gave signiﬁ  cantly 
greater reductions (−1.08% and −1.13%, respectively). At 
week 26, 42% of patients receiving 1.8 mg liraglutide reached 
the ADA recommended target of HbA1c of 7%, with 21% 
reaching 6.5%. FPG was reduced by both liraglutide and 
rosiglitazone combinations, compared to placebo, but with 
no signiﬁ  cant differences between the active treatments 
arms (reductions of −0.7 to −1.6 mmol/L). Whereas the 
rosiglitazone combination resulted in a signiﬁ  cant weight 
gain of 2.1 kg by week 26, in this study liraglutide had 
no major effect on weight compared with placebo (+0.7, 
+0.3 and −0.2 kg for 0.6, 1.2 and 1.8 mg liraglutide; −0.1 kg 
for placebo).33,34
In LEAD-2, the effect of liraglutide (0.6, 1.2 or 1.8 mg 
once daily) was examined in 1091 patients with T2DM 
(baseline HbA1c 8.4%) on background metformin (1 g twice 
daily) therapy in a placebo-controlled trial with glimepiride 
(4 mg/day) as an active comparator.35 This was a 26-week 
study, with an on-going 2-year continuation phase. Compared 
to placebo treatment, the addition of liraglutide to metformin 
signiﬁ  cantly reduced HbA1c (change from baseline, −0.7%, 
−1.0% and −1.0% for 0.6, 1.2 and 1.8 mg liraglutide, respec-
tively vs +0.1% for placebo), with the two highest doses 
of liraglutide demonstrating non-inferiority to glimepiride 
added to metformin (−1.0%). In the 1.8 mg liraglutide group, 
42% of patients reached target HbA1c of 7%, comparable 
to glimepiride (36%), but signiﬁ  cantly more than in the 
placebo group (11%), and 24% attained an HbA1c of 6.5% 
(compared to 22% on glimepiride and only 4% on placebo). 
FPG was significantly reduced by all active treatment 
combinations to a similar extent (−1.1 to −1.7 mmol/L vs 
+0.4 mmol/L for placebo). Postprandial glucose values in all 
liraglutide groups were reduced compared to placebo, with the 
1.2 and 1.8 mg doses (−2.3 and −2.6 mmol/L, respectively) 
giving similar results to glimepiride (−2.5 mmol/L). Addi-
tion of liraglutide produced dose-dependent decreases in 
body weight (−1.8 to −2.8 kg at week 26), which were 
signiﬁ  cantly greater than in the placebo group (−1.5 kg) for 
the two highest doses, and which contrasted with a 1.0 kg 
weight gain with glimepiride.35
The LEAD-3 study is a head-to-head comparison of 
monotherapy with liraglutide (1.2 or 1.8 mg once daily) or 
glimepiride (8 mg/day) in 746 patients with T2DM (baseline 
HbA1c 8.2%) over 52 weeks,36 with a further on-going 4-year 
extension period. Any previous treatment (OAD mono-
therapy of up to half the maximal dose) was discontinued Vascular Health and Risk Management 2009:5 204
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at randomization. At 1 year, HbA1c had decreased from 
baseline by 0.84% and 1.14% for 1.2 and 1.8 mg liraglu-
tide compared with a reduction of 0.51% for glimepiride, 
with both liraglutide doses being superior to glimepiride 
(Figure 2). More liraglutide-treated subjects reached HbA1c 
targets of 7% and 6.5% (51% and 27%, respectively 
for liraglutide 1.8 mg) compared to glimepiride (28% and 
16%, respectively). Fasting and postprandial glucose levels 
were dose-dependently reduced with liraglutide, with both 
liraglutide doses being superior to glimepiride (FPG, −0.8 
and −1.4 mmol/L for liraglutide vs −0.3 for glimepiride; 
postprandial glucose, −1.7 and −2.1 mmol/L for liraglutide 
vs −1.4 for glimepiride). Body weight declined over the ﬁ  rst 
16 weeks and thereafter stabilized on both liraglutide doses 
(−2.1 and −2.5 kg, respectively), in contrast to a weight gain 
of 1.1 kg with glimepiride.36
The effect of adding liraglutide (1.2 or 1.8 mg) to therapy 
of patients inadequately controlled on metformin (1 g twice 
daily) plus rosiglitazone (8 mg/day) was evaluated in LEAD-4, 
in 533 patients with T2DM (baseline HbA1c 8.3%) treated for 
26 weeks in a placebo-controlled trial; results were recently 
presented at the EASD.37 Addition of liraglutide signiﬁ  cantly 
reduced HbA1c to a greater extent than placebo, with both 
liraglutide doses being comparable (change from baseline, 
−1.48% for both liraglutide doses vs –0.54% for placebo). 
Of patients receiving liraglutide, 58% and 54% (1.2 and 
1.8 mg dose) reached target HbA1c of 7% (vs 28% for pla-
cebo), with 35% and 37% reaching values 6.5% (14% for 
placebo). The addition of liraglutide resulted in additional 
reductions in FPG and postprandial glucose, again with both 
liraglutide doses giving similar results (FPG, −2.2 and −2.4 
mmol/L; postprandial glucose, −2.7 and −2.6 mmol/L for the 
two liraglutide groups vs −0.4 and −0.8 mmol/L for placebo). 
Whereas patients on placebo treatment experienced a small 
increase in body weight (+0.6 kg), those on liraglutide lost 
weight, with the effect being dose-dependent (−1.0 and −2.0 
kg, respectively for 1.2 and 1.8 mg liraglutide).37
The LEAD-5 study examined the effect of adding lira-
glutide (1.8 mg once daily) to metformin (1 g twice daily) 
plus glimepiride (2–4 mg/day) in 581 patients with T2DM 
(baseline HbA1c 8.2%) in a placebo-controlled trial; insu-
lin glargine was used as an active comparator (open label). 
Preliminary results have been presented at both ADA and 
EASD.38,39 After 26 weeks, a greater reduction in HbA1c 
was obtained with liraglutide (−1.33%) than with either 
insulin glargine (−1.09%) or placebo (−0.24%) and more 
patients reached target HbA1c levels with liraglutide (52% 
reaching 7% and 36% reaching 6.5%) compared to 
insulin glargine (44% and 23%, respectively) or placebo 
(15% and 11%, respectively). Both active treatments 
reduced FPG to a similar extent (∼ −1.6 mmol/L), in con-
trast to placebo-treatment which resulted in a small increase 
(+0.6 mmol/L). In contrast to insulin glargine treatment, 
where patients gained weight (+1.6 kg), liraglutide resulted 
in a signiﬁ  cant weight loss of 1.8 kg from baseline (placebo, 
−0.4 kg from baseline).38,39
Finally, the LEAD-6 trial aimed to directly compare lira-
glutide (1.8 mg once daily) with exenatide (10 μg twice daily) 
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Figure 2 Effects of liraglutide monotherapy in LEAD-3. Eligible patients had been treated with diet and exercise only or up to half the highest dose of OAD monotherapy, 
which was discontinued at randomization.   Adapted from  The Lancet, Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 
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in 464 patients who were inadequately treated with metformin 
and/or a sulfonylurea (baseline HbA1c 8.2%). Preliminary 
results were presented at the Canadian Diabetes Association 
meeting.40 After 26 weeks, glycemic control was superior 
with liraglutide than with exenatide (HbA1c reductions of 
1.12% vs 0.79%; 54% vs 43% of subjects reaching target 
HbA1c of 7%; 35 vs 21% of subjects reaching HbA1c 
6.5%; FPG reductions of 1.6 vs 0.6 mmol/L; liraglutide 
vs exenatide). Body weight changes were similar for both 
groups (–3.2 kg for liraglutide, –2.9 kg for exenatide).40 In 
an extension of this study, patients originally randomized 
to exenatide were switched to liraglutide. After 14 weeks, 
HbA1c in these subjects had dropped by a further 0.3%, FPG 
by 0.9 mmol/L and body weight by 1 kg, so that there was 
no longer any signiﬁ  cant difference from those subjects who 
continued on liraglutide.41
Islet cell effects
In preclinical studies, liraglutide has been demonstrated 
to have protective effects on the β-cell. Thus, in cultured 
primary neonatal rat islets, Bregenholt et al42 showed that lira-
glutide inhibited both cytokine- and free fatty acid-induced 
apoptosis, while Friedrichsen et al 43 found that β-cell repli-
cation was increased, and similar effects in cultured human 
islets were recently reported.44 In animal studies, β-cell mass 
was increased following treatment with liraglutide in rodent 
models of T2DM.45,46
While effects on β-cell mass have not yet been demon-
strated in clinical studies (due primarily to a lack of suitable 
non-invasive technology), beneﬁ  cial effects on islet cell 
function have been consistently seen. Thus, a single dose 
of liraglutide restores β-cell sensitivity to glucose,47 while 
1 week of treatment improves glucose-induced insulin 
secretion and β-cell function (HOMA-β, insulin secretion 
during a hyperglycemic clamp, maximal insulin secretion 
after arginine infusion, proinsulin/insulin ratio) as well as 
having signiﬁ  cant effects on α-cell function (suppression 
of 24-hour glucagon proﬁ  les).25 The beneﬁ  cial effects on 
β-cell function were maintained over 12 weeks of treatment 
with the highest dose of liraglutide in the study of Madsbad 
et al.27 Assessment of β-cell function after 14 weeks of 
treatment with liraglutide revealed improvements in ﬁ  rst- 
and second-phase insulin secretion, together with increases 
in maximal (arginine-stimulated) insulin secretion during 
hyperglycemia.48 Another study, examining the effects of 
liraglutide under conditions of normal living, used math-
ematical modeling of insulin and glucose responses to meal 
ingestion, and also showed that liraglutide enhanced β-cell 
function.49 Finally, in the LEAD studies, liraglutide has 
been associated with improved β-cell function, which was 
similar to that observed with glimepiride,35,36 and superior 
to rosiglitazone33,34 or exenatide.40
Cardiovascular effects
Small increases in pulse rate of 2 to 3 beats per minute 
have been observed throughout the LEAD studies,35–37 
although the clinical signiﬁ  cance (if any) of this is unknown. 
However, of great interest are the consistent observations 
that systolic blood pressure is significantly decreased. 
Vilsbøll et al30 found reductions with all liraglutide doses, 
by up to 7.9 mmHg compared to placebo after 14 weeks of 
treatment. In LEAD-2 and LEAD-3, systolic blood pressure 
changes favored liraglutide over glimepiride (reductions from 
baseline of 2–4 mmHg with liraglutide).35,36 Reductions in 
systolic blood pressure were also reported for the other LEAD 
studies, with the effects already apparent at the ﬁ  rst assess-
ment point (2 weeks post-randomization).50 No signiﬁ  cant 
changes in diastolic blood pressure were reported in any of 
the studies.
Adverse events and safety
Gastrointestinal side effects
In common with other GLP-1 receptor agonists, such as 
exenatide, gastrointestinal adverse effects (nausea, vomiting 
and diarrhea) are the most common adverse events seen in the 
clinical trials with liraglutide, with the incidences appearing 
to be dose-related.
Thus, throughout the LEAD studies, up to 44% of 
subjects receiving liraglutide at the highest dose (1.8 mg) 
reported gastrointestinal side effects, with nausea being the 
most frequently reported event, occurring in up to 40% of 
subjects. Generally, nausea was seen predominantly in the 
ﬁ  rst few weeks after initiation of treatment; in LEAD-2, 
less than 10% of the subjects were experiencing nausea 
on a weekly basis by the fourth week.35 In LEAD-1 and 
LEAD-5, nausea was reported by less than 4% of subjects 
by week 2 to 4,33,34,38,39 while in LEAD-4, the incidence of 
nausea had decreased to the same level as in the placebo 
group after 16 weeks.37 Diarrhea was reported by 15% to 
18% of subjects compared to less than 10% of subjects on 
comparator agents,35,36 and vomiting by ∼10% of subjects 
(vs 4% on glimepiride).35 However, it is noteworthy that 
relatively few subjects withdrew from the studies because 
of gastrointestinal side effects associated with liraglutide. In 
LEAD-2, only 5% of all liraglutide treated subjects withdrew, 
with the majority of those discontinuing during the ﬁ  rst Vascular Health and Risk Management 2009:5 206
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month of treatment,35 while in LEAD-3, between 2% and 4% 
of subjects withdrew.36 In a speciﬁ  cally designed sub-study, 
a Gastrointestinal System Rating Scale (GSRS; a validated 
self-reporting method) was used to quantify the duration and 
intensity of gastrointestinal adverse events during 14 weeks 
of liraglutide treatment (0.65, 1.25 and 1.9 mg).51 Although 
liraglutide increased gastrointestinal symptoms, the average 
rating was low (maximum 2 on a 7-point scale), with the 
self-reported increase in events occurring mainly during the 
ﬁ  rst two weeks of treatment, and decreasing thereafter. Only 
the reﬂ  ux GSRS score showed a signiﬁ  cant dose-related rela-
tionship. For indigestion and constipation, only the 1.25 mg 
dose was signiﬁ  cantly greater than placebo, while there was 
no difference between liraglutide and placebo with respect 
to scores for diarrhea and abdominal pain.51
Hypoglycemia
Overall, the risk of hypoglycemia with liraglutide is low, 
due to the glucose-dependency of its insulinotropic and 
glucagonostatic effects. Under conditions of a stepwise 
hypoglycemic clamp, insulin secretion is no longer enhanced 
by liraglutide (7.5 μg/kg) when blood glucose levels are 
reduced from 3.7 to 3.0 mmol/L and there is no impairment 
of hypoglycemia-induced glucagon secretion,52 suggesting 
that the counter-regulatory response to hypoglycemia is 
unaffected by liraglutide. Thus, in the early clinical studies, 
minor hypoglycemia (deﬁ  ned as 3.1 mmol/L) was rarely 
observed.27–30
Throughout the LEAD program, the incidence of minor 
hypoglycemia with liraglutide has also been very low, 
ranging from 0.03 up to 1.9 events per year.33–40 Overall, in 
the studies with active comparators, the incidence has been 
similar to that observed with metformin or rosiglitazone,33,34 
and lower than that seen with glimepiride35,36 or exenatide.40 
Major hypoglycemia has only rarely been seen. In LEAD-1, 
one major hypoglycemic episode was reported, although this 
was considered to be related to the background sulfonylurea 
therapy,33,34 while in LEAD-5, 2.2% of subjects experienced 
a major hypoglycemic event in the liraglutide arm (vs none 
in the other arms).38,39
Pancreatitis
Novo Nordisk has reported a low number of incidents of 
acute pancreatitis in patients taking liraglutide in the clinical 
trials, although the incidence rate is in the normal range for 
T2DM; no cases of hemorrhagic or necrotizing pancreatitis 
have been seen.41 In LEAD-3, 2 participants (out of 498 
taking liraglutide) experienced pancreatitis, 1 after 197 days 
(1.2 mg dose) and 1 after 333 days (1.8 mg dose); both 
recovered and 1 continued in the study.36 In LEAD-2, 1 subject 
(out of 724) in the liraglutide-exposed group (1.2 mg) and 
1 (out of 242) in the glimepiride group withdrew because 
of acute pancreatitis; after hospitalization for 7 days, both 
recovered.35 No incidents of pancreatitis were reported in the 
LEAD-4 trial.37
Antibodies
Formation of anti-liraglutide antibodies is reported to be low 
and not to be associated with loss of efﬁ  cacy.41 In LEAD-2, 
antibodies were detected in only 1 (out of 85) of the subjects 
who did not enter the open-label continuation phase of the 
study at week 26, and these were not immuno-neutralizing 
and showed no cross-reactivity with GLP-1.53 Liraglutide 
antibodies were found in 9.3% to 12.7% of liraglutide-
treated subjects in LEAD-1,33,34 and in 9.8% in LEAD-5 
after 26 weeks.38,39
Discussion
Liraglutide belongs to one class of the so-called incretin-
based therapies, namely the incretin mimetics (the other 
class being the DPP-4 inhibitors), which takes advantage 
of the known effects of the intestinal hormone, GLP-1. At 
present, clinical experience with these agents is still relatively 
limited, with exenatide being the only incretin mimetic so far 
to be approved for treatment of T2DM (launched in 2005). 
In clinical trials, both liragutide and exenatide have been 
well tolerated, with gastrointestinal adverse events (nausea, 
diarrhea, vomiting) being the most common side effects 
(reported by ∼50% of subjects). However, gradual dose 
escalation seems effective in reducing the incidence and 
severity of these gastrointestinal symptoms, such that in the 
majority of trials, their frequency was highest at the initiation 
of therapy and declined thereafter. Some concern over the 
safety of the incretin mimetics ﬁ  rst arose in 2007, after the 
FDA issued a warning following reports of acute pancreatitis 
in patients taking exenatide; 30 cases were reported, although 
the diagnosis of acute pancreatitis (based on the presence of 
nausea, vomiting, abdominal pain, which notably are also 
known side effects of the incretin mimetics themselves) was 
conﬁ  rmed by laboratory test in only 17 of the cases, and 27 of 
the cases had at least one other risk factor. Subsequently a 
total of 89 cases in patients on exenatide had been reported 
up to the end of September 2007. In August 2008, the FDA 
reported 6 new cases of hemorrhagic or necrotizing pancre-
atitis in patients using exenatide, and 6 deaths in patients who 
had experienced pancreatitis have been reported, although Vascular Health and Risk Management 2009:5 207
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other confounding factors were involved.54,55 However, the 
rates of pancreatitis with exenatide56 or liraglutide41 are below 
those reported for the background T2DM population, which 
itself has a 2.8-fold greater incidence than the general popu-
lation.57 At present, a deﬁ  nitive causal relationship between 
incretin mimetics and pancreatitis has not been established, 
but a possible association cannot yet be fully excluded.
Consistent with the glucose dependency of its mechanism 
of action, the incidence of hypoglycemia has been very low 
with liraglutide, although occasional episodes of severe hypo-
glycemia have been noted when used in combination with 
sulfonylurea.33,34,38,39 A greater incidence of hypoglycemia 
has also been observed when exenatide is used together with 
sulfonylurea,58,59 and may perhaps reﬂ  ect the enhanced β-cell 
function brought about by the GLP-1 agonists. Alternatively, 
there is some preclinical evidence that the sulfonylurea itself 
can uncouple the glucose-dependency of GLP-1’s insulino-
tropic action.60
Weight loss with liraglutide in some trials has been 
inconsistent. In some of the earlier studies, no clear dose-
response relationship was apparent,26–28 but this might be 
explained by the doses used in these studies not being 
optimal. With the higher doses (up to 1.9 mg), weight reduc-
tions have generally been seen consistently, although rather 
surprisingly, in LEAD-1, the weight change was not different 
from placebo.33,34 It has also been questioned whether nausea 
contributes to the weight loss observed with the GLP-1 
analogs. In a sub-group analysis in LEAD-3, there were 
small trends for the magnitude of weight loss to be greater in 
subjects experiencing nausea for more than 7 days compared 
to those with none or less than 7 days’ nausea (eg, for 1.8 mg 
liraglutide, the weight change was −3.4 kg for participants 
experiencing nausea for more than 7 days vs −2.3 kg for those 
with none or less than 7 days’ nausea), although the differ-
ences were not signiﬁ  cant for any treatment.36 Liraglutide 
appears not to affect energy expenditure, at least in doses up 
to 0.6 mg,26 while with higher doses (up to 1.8 mg), there was 
only a non-signiﬁ  cant trend for resting energy expenditure to 
be higher.61 It therefore appears that the major cause of weight 
loss is due to reduction in food intake. Thus, in sub-studies 
using visual analog scales, liraglutide reduced the feelings 
of hunger and prospective food intake, while increasing the 
feeling of fullness, together leading to a lower energy intake 
by up to 18% during an ad libitum meal.61,62
Any anti-diabetic agent that shows beneﬁ  cial effects on 
the development of diabetic macrovascular complications 
will be welcome. Cardioprotective effects of GLP-1 have 
been observed preclinically,63 and it is therefore of particular 
interest that liraglutide treatment has been associated with 
clinically signiﬁ  cant reductions in systolic blood pressure. 
This may be partly accounted for by concomitant body weight 
loss, although based on the proﬁ  les over time, Nauck et al35 
concluded that weight reductions could not fully explain 
the blood pressure changes. It is therefore noteworthy that 
reductions in blood pressure are also observed with the DPP-4 
inhibitors, which are weight neutral.64,65 Additionally, there 
is some evidence that the weight loss induced by liraglutide 
comes pimarily from loss of fat (particularly visceral fat, 
which is a known cardiovascular risk factor), rather than 
lean tissue.66 Whether these changes will be associated with 
reductions in macrovascular events will become apparent as 
clinical experience with these agents is gained and as data 
from longer duration trials with cardiovascular endpoints 
become available.
It is clear from the clinical trials that liraglutide improves 
glycemic control via effects on both fasting and postpran-
dial glucose. The islet effects are likely to be of particular 
importance, since liraglutide has been consistently shown to 
improve β-cell function, leading to increased fasting insulin 
levels and improved maximal postprandial insulin levels.67 
Additionally, effects on the α-cell are also likely to be impor-
tant, given liraglutide’s powerful glucagonstatic effect.25 
However, unlike exenatide, where delayed gastric emptying 
appears to play a major role in the drug’s antihyperglycemic 
action,68 delayed gastric emptying probably accounts for a 
smaller part of the lower postprandial glucose levels obtained 
with liraglutide. Thus, while a single dose of liraglutide 
does signiﬁ  cantly delay gastric emptying,24 liraglutide was 
without effect on gastric emptying when administered over 
several weeks, although the doses used in those early studies 
may not have been optimal.25,26 Subsequently, studies using 
higher doses (up to 1.8 mg) have indicated that liraglutide is 
associated with a minor delay in gastric emptying, particu-
larly over the ﬁ  rst hour.61,67 This difference in the relative 
effects of exenatide and liraglutide on gastric emptying may 
be explained by the more prolonged exposure to liraglutide 
leading to some tachyphylaxis of the gastric emptying effect, 
speculation which is supported by the observation that a 
long-acting formulation of exenatide, designed for once-
weekly administration, has a less pronounced effect on gastric 
emptying (and postprandial glucose excursions) than exena-
tide given twice daily.69 Although there is some evidence that 
some of the effects of endogenous GLP-1 may be mediated 
via interaction with autonomic nerves, at present it is unclear 
whether any of the effects of exogenously administered 
GLP-1 analogs depend on autonomic function. However, it Vascular Health and Risk Management 2009:5 208
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is noteworthy that GLP-1 is still able to normalize fasting 
glucose levels when given intravenously to patients with 
advanced diabetes, long after secondary sulfonylurea failure, 
in whom neuropathy is present.70 Furthermore, a recent study 
indicates that the gastric emptying effects of exenatide are 
unaffected by the presence of autonomic neuropathy.68
Early studies with native GLP-1 indicated that increasing 
the exposure to the peptide resulted in greater efﬁ  cacy with 
respect to lowering blood glucose levels,71,72 and a similar 
situation seems to exist with the GLP-1 analogs. The ﬁ  rst 
GLP-1 analog to be used for treatment of T2DM, exenatide, 
has a pharmacokinetic proﬁ  le necessitating twice daily 
administration. In clinical use, exenatide gives sustained 
reductions in HbA1c levels,73 but because of its relatively 
short plasma half-life, exposure to the drug is not optimal, 
even with twice-daily administration, particularly so in the 
overnight period. Liraglutide, with its longer plasma half-life, 
provides 24-hour coverage, and the preliminary results of 
the head-to-head comparison indicate that glycemic control 
is superior with liraglutide.40 Similar results have also been 
seen with the once-weekly formulation of exenatide.69 More-
over, the ﬂ  atter drug proﬁ  le obtained with these longer-acting 
analogs69,74 also seems to reduce gastrointestinal symptoms. 
The DPP-4 inhibitors also increase intact GLP-1 levels over 
the full 24-hour period, but the pattern of exposure differs. 
Thus, whereas the GLP-1 analogs raise agonist plasma 
concentrations into the pharmacological range throughout 
the vascular system, the DPP-4 inhibitors typically increase 
intact GLP-1 concentrations by only 2- to 3-fold,75 although 
with concentrations locally in the gut and portal vein being 
much higher than those in the periphery.76 It has been argued 
that GLP-1 may exert many of its actions locally or in the 
hepato-portal bed,77 and perhaps because of this, the DPP-4 
inhibitors are effective, despite the low systemic GLP-1 
concentrations attained. Like the GLP-1 analogs, DPP-4 
inhibitors give sustained reductions in HbA1c,78 and are asso-
ciated with improvements in β-cell function.79, 80 Similarly, 
α-cell function is also improved with DPP-4 inhibitors,81 but 
unlike the GLP-1 analogs, there are only minimal effects 
of gastric emptying and appetite is unaffected,82 meaning 
that the DPP-4 inhibitors are best described as being body 
weight neutral. While the mechanism of action of the GLP-1 
analogs relies only on GLP-1 receptor signaling, the DPP-4 
inhibitors are believed to exert their effects via endogenous 
GLP-1 and GIP, but precisely how this difference affects the 
clinical proﬁ  les of the two classes of agents remains to be 
elucidated. The HbA1c-lowering efﬁ  cacy of the two classes 
of incretin-based therapies has not yet been directly compared, 
although a mechanistic study over 2 weeks indicated that while 
both agents had similar effects on FPG, exenatide had a greater 
effect on breakfast and dinner (but not lunch) postprandial 
glucose,82 presumably related to the potent effect of exenatide 
to reduce gastric emptying.
The positioning of liraglutide in the therapeutic regimen 
remains to be determined. In support of an early use, the 
LEAD program indicates that liraglutide is effective in mono-
therapy, and even superior to sulfonylurea, with the additional 
advantage of weight loss and less hypoglycemia.36 Moreover, 
as add-on therapy to a single OAD, it is non-inferior to 
sulfonylurea,35 and superior to thiazolidinedione,33,34 again 
with the favorable effect on weight. Moreover, various 
sub-group analyses seem to indicate that the degree of 
improvement is, at least partially, related to the stage of the 
disease. Thus, subjects previously treated with diet and 
exercise achieved greater HbA1c reductions than those who 
had previously been on OAD monotherapy in LEAD-3.36 
In LEAD-1, subjects previously on OAD monotherapy 
achieved greater HbA1c reductions than those on previous 
combination therapy,33,34 while in LEAD-2, there was a 
tendency for those who were on pre-study monotherapy to 
achieve greater HBA1c reductions than those on previous 
combination therapy.35 However, whether there will be 
patient (and physician) acceptance of using an injectable 
agent early in the management of the disease has yet to be 
determined. There is also a place for liraglutide later on in 
the course of the disease, with liraglutide giving signiﬁ  cant 
reductions in HbA1c when used as an additional agent in 
patients already receiving combination therapy with 2 or 
3 OADs,37–39 and compared with insulin glargine, liraglutide 
gave better glycemic control without the weight gain.37,38 
Particularly the weight changes may help to encourage the 
use of this agent, since, with the exception of the incretin-
based therapies (GLP-1 analogs and DPP-4 inhibitors) 
and metformin, all other agents, including insulin, are 
associated with weight gain. However, if lasting effects 
on the β-cell are demonstrated, then liraglutide (and other 
incretin-based therapies) may be able to ameliorate the 
progressive deterioration in glycemic control, which, at 
present, seems an inescapable characteristic of T2DM. It is 
therefore encouraging that preliminary results from a study 
in obese non-diabetic subjects, where around 30% of the 
participants had some signs of prediabetes at randomization, 
indicated that liraglutide was associated with a reduction in 
the number of prediabetic subjects after 1 year of treatment.83 
The success of liraglutide will ultimately depend upon not 
only its efﬁ  cacy and durability in terms of glycemic control Vascular Health and Risk Management 2009:5 209
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and body weight, but also upon its possible impact on late 
diabetic complications, and compliance issues such as toler-
ability/safety, convenience of use and cost.
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